Sugi Predict

Sugi Predict / Compounds / SCHEMBL7229498

SCHEMBL7229498

SCHEMBL7229498

CCOC(=O)C(=CN(C)C)C(=O)c1cc2cc(F)c(F)c(F)c2nc1Cl

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 5/20 0.35
▸ TSHR P16473 1/20 0.34
▸ MEN1 O00255 3/20 0.33
▸ KMT2A Q03164 3/20 0.33
▸ MAPT P10636 3/20 0.33
▸ CYP2C9 P11712 2/20 0.33
▸ LMNA P02545 2/20 0.33
▸ NPSR1 Q6W5P4 2/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ CYP11B1 P15538 5/20 0.33
▸ CYP11B2 P19099 5/20 0.33
▸ ATM Q13315 1/20 0.32
▸ ALDH1A1 P00352 3/20 0.32
▸ KDM4E B2RXH2 1/20 0.32
▸ NPY1R P25929 1/20 0.32
▸ NPY2R P49146 1/20 0.32
▸ PTPN11 Q06124 1/20 0.31
▸ GAA P10253 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7229496 1.00 HPGD (0.35) HPGDTSHRMEN1KMT2AMAPT
SCHEMBL6607390 0.85 KEAP1 (0.35) CYP11B1CYP11B2
SCHEMBL6607388 0.85 KEAP1 (0.35) CYP11B1CYP11B2
SCHEMBL7237682 0.85 ATM (0.40) HPGDTSHRMEN1KMT2AMAPT
SCHEMBL7237684 0.85 ATM (0.40) HPGDTSHRMEN1KMT2AMAPT
SCHEMBL13756506 0.84 KEAP1 (0.44) HPGDMEN1KMT2AMAPTCYP2C9
SCHEMBL31696352 0.84 KEAP1 (0.44) HPGDMEN1KMT2AMAPTCYP2C9
SCHEMBL9562369 0.84 KEAP1 (0.44) HPGDMEN1KMT2AMAPTCYP2C9
SCHEMBL9775894 0.83 ATM (0.39) HPGDTSHRMEN1KMT2AMAPT
SCHEMBL9775897 0.83 ATM (0.39) HPGDTSHRMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6548506-B2 1-substituted,3-carboxy,7-fluoro,8-disubstituted amino-1,4-dihydrobenzo(b)(1,8)naphthyridin-4-ones; Useful as antimicrobial agents; topical antibiotic for wounds AVENTIS PHARMA S.A. (FR) 2003-04-15 — — US disclosed
US-20020037891-A1 Novel benzo[1,8]naphthyridine derivatives, their preparation and pharmaceutical compositions which comprise them AVENTIS PHARMA S.A. (FR) 2002-03-28 — — US disclosed
US-5053509-A Microbiocides; AIDS LABORATOIRE ROGER BELLON (FR) 1991-10-01 — — US disclosed
US-5004745-A Benzo[1,8]naphthyridine derivatives, their preparation and the compositions which contain them LABORATOIRE ROGER BELLON (FR) 1991-04-02 — — US disclosed
US-4990515-A Chemical intermediates RHONE-POULENC SANTE (FR) 1991-02-05 — — US disclosed
US-4970213-A Benzo(1,8)naphthyridine derivatives as intermediates RHONE-POULENC SANTE (FR) 1990-11-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020037891-A1 Novel benzo[1,8]naphthyridine derivatives, their preparation and pharmaceutical compositions which comprise them ABCB11, NDUFA9, NDUFC1 HPGD 528/4885TSHR 4376/4885MEN1 2627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.